Processing and Presentation of Minor Histocompatibility Antigens that Cause GvHD
Processing and Presentation of Minor Histocompatibility Antigens that Cause GvHD
批准号:
9269291
负责人:
SEBASTIAN JOYCE
金额:
$39.5万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-15 至 2018-04-30
关键词:
AlloantigenAnemiaAntigensAutophagocytosisBackBiochemicalBlood CellsBone Marrow TransplantationCD4 Positive T LymphocytesCell physiologyCellsCross PresentationCytoplasmCytosolDendritic CellsDiseaseGoalsHistocompatibilityHistocompatibility Antigens Class IImmunologic Deficiency SyndromesKnockout MiceLeadListeriaListeria monocytogenesLysosomesMHC Class II GenesMajor Histocompatibility ComplexMediatingMicrobeMinorMinor Histocompatibility AntigensModalityMolecular ChaperonesMusOrgan TransplantationOrphanOutcomePathogenesisPeptide HydrolasesPeptidesPeripheralPlasmodiumPlayProcessProteinsReportingResearchRoleSolidStagingT cell responseT-LymphocyteTAP1 geneTAP2 geneTestingTherapeuticTimeTransplantationVaccine DesignViralViral AntigensWorkantigen processingbacterial H antigendimergraft vs host diseaseimprovedinsightleukemia/lymphomamalemicrobialmicroorganism antigenmulticatalytic endopeptidase complexnovelpathogenresponsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Minor histocompatibility (H) antigens (Ags) play a detrimental role in the immuno-pathogenesis of graft-vs-host
disease (GvHD) even in recipients of HLA identical bone marrow transplants. Herein, recipient minor H Ags are
acquired by donor Ag-presenting cells (APCs) and processed and presented either by MHC class I molecules
in a well studied process termed cross-presentation or by class II molecules in a less well understood process
called indirect presentation. In a solid organ transplant setting, indirect presentation entails the acquisition,
processing and presentation of donor alloantigens by the recipient's APCs. In the case of tumour and microbial
Ags, a class II+ APC-likened to a recipient cell-acquires the Ag residing in a class II-negative cell-likened to
a donor cell-and processes and presents it to cognate CD4+ (TH) cells. Our mechanistic studies into indirect
presentation revealed that the male pHY and Listeria monocytogenes-derived pLLO Ags upon acquisition by
the recipient APCs gained access to the cytosol. Herein, the indirect presentation of pHY was
immunoproteasome-dependent yet TAP (cytosol to ER peptide transporter)- and ERAAP (ER-associated
amino-peptidase)-independent. Surprisingly, both TAP and ERAAP either diverted or destroyed pHY and pLLO
thereby reducing their presentation to TH cells. These finding led to two critical questions: (a) does the class I
Ag processing (CAP) machinery globally impact class II-restricted Ag presentation; and (b) how do cytosolic
Ags gain access to the endo/lysosomes for indirect presentation? In trying to understand how the cytosolic
pHY returned to the endo/lysosomes for presentation, we ruled out the role for macro-autophagy as indirect
presentation of HY proceeded in mice in which dendritic cells were conditionally deficient for Atg5. Instead, we
found that the homodimeric TAP-like (TAP-L)-an orphan endo/lysosomal peptide transporter distinct from ER-
resident TAP1/TAP2-was needed for indirect pHY presentation. Predicated on our functional studies, herein,
we seek to gain biochemical insights into indirect presentation mechanism(s). Hence, we will test the central
hypothesis that the class I Ag processing machinery regulates the pool of certain cytosolic Ags available for
class II-restricted indirect presentation. Such Ags are processed in the cytosol and transported to the endo/
lysosomes in a TAP-L-dependent mechanism. To test this hypothesis, we will (a) determine whether the CAP
machinery globally impacts H2Ab-restricted processing and presentation of self- or microbe-derived cytosolic
Ags; (b) determine how cytosolic Ags enter the endo/lysosomes for indirect presentation; and (c) determine
whether the CAP machinery impacts cytosolic Ag specific CD4+ T cell repertoire. Successful completion of this
work will yield new biochemical insight(s) into indirect Ag presentation by class II molecules. A mechanistic
understanding of class II-restricted indirect Ag presentation is critical not only for developing ways to
circumvent/treat GvHD but also for vaccine design as this process is operative in the presentation of cytosolic
Ags (viral, bacterial, parasitic) to TH cells and, hence, for vaccine design against tumours and pathogens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vaccinating at Mucosal Surfaces with Nanoparticle-conjugated Antigen and Adjuvant
-
批准号:10587388
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:SEBASTIAN JOYCE
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10454202
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Molecular Basis of CD1D and Natural Killer T Cell Function
-
批准号:10203802
-
项目类别:
-
资助金额:$51.62万
-
财政年份:2019
-
负责人:SEBASTIAN JOYCE
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:9911970
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Molecular Basis of CD1D and Natural Killer T Cell Function
-
批准号:10443746
-
项目类别:
-
资助金额:$51.05万
-
财政年份:2019
-
负责人:SEBASTIAN JOYCE
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:9766685
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:SEBASTIAN JOYCE
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10265366
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:SEBASTIAN JOYCE
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10618275
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting
-
批准号:10436179
-
项目类别:
-
资助金额:$44.76万
-
财政年份:2018
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting
-
批准号:10180937
-
项目类别:
-
资助金额:$45.54万
-
财政年份:2018
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and Adjuvant
-
批准号:8974276
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and Adjuvant
-
批准号:8822136
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and Adjuvant
-
批准号:10265410
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Processing and Presentation of Minor Histocompatibility Antigens that Cause GvHD
-
批准号:8614968
-
项目类别:
-
资助金额:$39.21万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and Adjuvant
-
批准号:8633616
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Processing and Presentation of Minor Histocompatibility Antigens that Cause GvHD
-
批准号:9250188
-
项目类别:
-
资助金额:$39.5万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and Adjuvant
-
批准号:9750508
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and Adjuvant
-
批准号:9898281
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and Adjuvant
-
批准号:10612330
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:SEBASTIAN JOYCE
-
依托单位:
Molecular Basis of iNKT Cell Ontogeny and Function
-
批准号:8121825
-
项目类别:
-
资助金额:$24.27万
-
财政年份:2010
-
负责人:SEBASTIAN JOYCE
-
依托单位:
国内基金
海外基金
基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
-
批准号:82302715
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:熊泽康
-
依托单位:
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2021
-
负责人:陈英伟
-
依托单位:
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
-
批准号:31200592
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:孙伟力
-
依托单位: